Alivus Life Sciences · NSE: ALIVUS · BSE: 543322
Q2 FY26 results · Jul–Sep 2025
Alivus Life Sciences reported revenue from operations of ₹587.98 crore (up 16.0% from Q2 FY25) and net profit of ₹130.03 crore (up 36.4% from Q2 FY25) for Q2 FY26 (Jul–Sep 2025), on a standalone basis.
| Item | Q2 FY26 | Q2 FY25 | YoY | Q1 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 587.98 | 506.88 | +16.0% | 601.85 | −2.3% |
| Other income | 14.72 | 8.53 | +72.5% | 8.98 | +63.8% |
| Total income | 602.70 | 515.41 | +16.9% | 610.83 | −1.3% |
| Profit before tax | 174.14 | 127.46 | +36.6% | 162.98 | +6.8% |
| Net profit for the period | 130.03 | 95.32 | +36.4% | 121.53 | +7.0% |
| EPS, basic (₹) | 10.60 | 7.78 | +36.2% | 9.91 | +7.0% |
| Net margin (%) | 22.1 | 18.8 | 20.2 |
Standalone
- Filed with BSE
- 06 Nov 2025, 19:11 IST
- Board meeting
- 06 Nov 2025
- Period
- 01 Jul 2025 to 30 Sep 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE